JAK2 and acquired polycythemia vera: In a study including 140 cases with CMDs, the rates of JAK2 mutation were found to be 82% (23.28) in PV cases, 53.1% (17.32) in ET patients, 40% (4.10) in PMF cases, and 60% (6.10) in other indistinguishable CMDs cases, respectively (7).